215 patents
Page 7 of 11
Utility
GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof
11 Nov 21
The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.
Brett P. Monia, Thazha P. Prakash, Garth A. KINBERGER, Richard Lee, Punit P. Seth, Shalini Andersson, Eva Carina Ämmälä, Daniel Laurent Knerr, Maria Astrid Ölwegård-Halvarsson, Eric Valeur, William John Drury, III
Filed: 15 Apr 21
Utility
Deuterated Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer
11 Nov 21
Kurt Gordon PIKE, Bernard Christophe BARLAAM
Filed: 20 Jul 21
Utility
Methods and Compositions for Reducing Serum Uric Acid
4 Nov 21
The present disclosure provides compositions comprising verinurad, a xanthine oxidase inhibitor, and dapagliflozin useful in the reduction of serum uric acid levels, formulations containing them, and methods using them.
Johan HOEGSTEDT, James MACKAY, Eva JOHNSSON
Filed: 1 Oct 18
Utility
Pharmaceutical Formulations
28 Oct 21
The present specification relates to pharmaceutical formulations comprising N-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine, microcrystalline cellulose (MCC) and dicalcium phosphate anhydrous (DCPA), for example tablets with immediate release properties.
Farhan Abdel Karim Mohammad AL HUSBAN
Filed: 22 Apr 21
Utility
Dosage Regimen for the Treatment of Cancer
28 Oct 21
The present specification relates to AZD9833 for use in the treatment of cancer and methods of treatment of cancer involving administration of AZD9833 wherein, in each case, the AZD9833 is administered orally once daily at a dose between 25 mg and 450 mg.
Pablo MORENTIN GUTIERREZ, Camila DE ALMEIDA, Eric Todd GANGL
Filed: 22 Apr 21
Utility
Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors
28 Oct 21
This disclosure relates to compositions and methods for treating cancer using armored chimeric antigen receptor cells.
GORDON MOODY, MARIA LETIZIA GIARDINO-TORCHIA, MICHAEL GLEN OVERSTREET, RYAN GILBRETH
Filed: 22 Apr 21
Utility
Arginase Inhibitors and Methods of Use thereof
28 Oct 21
Dedong WU
Filed: 21 Aug 19
Utility
Methods Comprising Fixed Intermittent Dosing of Cediranib
21 Oct 21
Methods comprising repeating cycles of administration of a composition comprising cediranib according to a fixed intermittent dosing regimen comprising administration of an effective amount of the composition comprising cediranib on one or more consecutive days of a cycle followed by one or more consecutive days of rest on which said composition is not administered are disclosed herein, and may be used as monotherapy or may comprise administration of one or more partner drugs or therapies and may be used in combination therapy.
Simon BARRY, Jane KENDREW, Tony HO, Stephen Robert WEDGE, Susan Percy IVY, Elise KOHN, Jung-Min LEE
Filed: 14 Feb 17
Utility
Combination Therapy for Treating Cancer
14 Oct 21
Disclosed are methods of treating cancer comprising administering to a subject in need thereof comprising administering to the subject an effective amount of a pharmaceutical composition comprising a plurality of AZD2811 nanoparticles and an effective amount of 5-azacitidine.
Wolfram BRUGGER
Filed: 26 Jul 19
Utility
Exosome Extracellular Vesicles and Methods of Use
14 Oct 21
Exosomes comprising a modified RNA are disclosed.
Hadi VALADI, Lennart LINDFORS
Filed: 27 Jun 19
Utility
Linkers and conjugates
7 Oct 21
Jeremy Stephen Parker, Hannah Fiona Sore, David Robert Spring, Stephen James Walsh
Filed: 31 Jul 18
Utility
Chemical Compounds
16 Sep 21
Bernard Christophe BARLAAM, Daniel Hillebrand O'DONOVAN, Samantha Jayne HUGHES, Thomas Andrew MOSS, Johannes Wilhelmus Maria NISSINK, James Stewart SCOTT, Bin YANG
Filed: 17 Feb 21
Utility
Methods of Treating Heart Failure with Reduced Ejection Fraction
26 Aug 21
The present disclosure is directed to methods of treating patients with heart failure with reduced ejection fraction (HFrEF), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.
Anna Maria LANGKILDE
Filed: 25 Feb 21
Utility
Dual Inhibitors of Phosphatidylinositol 3-KINASE Delta & Gamma
12 Aug 21
Matthew PERRY, Christian TYRCHAN, Konstantinos KARABELAS, Antonios NIKITIDIS, Mickael MOGEMARK, Jens PETERSEN, Peter BOLD, Ulf BORJESSON
Filed: 11 Feb 21
Utility
Certain (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES As Dipeptidyl Peptidase 1 Inhibitors
5 Aug 21
Hans Roland LÖNN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
Filed: 8 Feb 21
Utility
MCL-1 Inhibitors and Methods of Use Thereof
29 Jul 21
Alexander HIRD, Matthew BELMONTE, Wenzhan YANG, Paul SECRIST, Daniel ROBBINS, Steven KAZMIRSKI, Dedong WU, Bo PENG, Jeffrey JOHANNES, Michelle LAMB, Qing YE, XiaoLan ZHENG
Filed: 4 Dec 20
Utility
1-[2-(AMINOMETHYL)BENZYL]-2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE
29 Jul 21
Tord Bertil INGHARDT, Petra JOHANNESSON, Ulrik JURVA, Erik MICHAELSSON, Eva-Lotte LINDSTEDT-ALSTERMARK, Nicholas TOMKINSON, Jeffrey Paul STONEHOUSE, Li-Ming Gan
Filed: 12 Apr 21
Utility
Inducible Modification of a Cell Genome
29 Jul 21
The present disclosure is directed, in some embodiments, to compositions and methods for inducible modification of a cell genome.
Marcello MARESCA, Mohammad BOHLOOLY-YEGANEH, Himjyot JAISWAL, Lorenz M. MAYR, Xiufeng XU
Filed: 3 Feb 21
Utility
Tetracyclic Heteroaryl Compounds
22 Jul 21
Jason Grant KETTLE, Sharanjeet Kaur BAGAL, Andrew John EATHERTON, Shaun Michael FILLERY, Graeme Richard ROBB, Scott Gibson LAMONT, Paul David KEMMITT, Frederick Woolf GOLDBERG
Filed: 7 May 19
Utility
Halo-substituted Piperidines As Orexin Receptor Modulators
15 Jul 21
The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
Theodore M. Kamenecka, Jörg Holenz, Steven Wesolowski, Yuanjun He, Roland Bürli
Filed: 9 Dec 20